Alexa P Kollmeier (A P Kollmeier, Alexa Kollmeier)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 19

Top Topics

Breast Cancer Cells

Endoplasmic Reticulum

Juvenile Idiopathic Arthritis

Top Venues

Clinical rheumatology

Arthritis & rheumatology (Hoboken, N.J.)

Rheumatology and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Stefan Siebert, Laura C Coates, Larissa Valor-Méndez, Siba P Raychaudhuri, Warner Chen, Sheng Gao, Loqmane Seridi, Soumya D Chakravarty, May Shawi, Frederic Lavie, Mohamed Sharaf, Miriam Zimmermann, Alexa P Kollmeier, Xie L Xu, Proton Rahman, Phillip J Mease, Atul A Deodhar
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis. Arthritis & rheumatology (Hoboken, N.J.) 76 (6) (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology (2024)
Jeffrey R Curtis, Iain B McInnes, Proton Rahman, Dafna D Gladman, Steven Peterson, Feifei Yang, Oluwakayode Adejoro, Alexa P Kollmeier, Natalie J Shiff, Chenglong Han, May Shawi, William Tillett, Phillip J Mease
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis. Rheumatology and therapy 11 (2) (2024)
Jeffrey R Curtis, Iain B McInnes, Proton Rahman, Dafna D Gladman, Steven Peterson, Feifei Yang, Oluwakayode Adejoro, Alexa P Kollmeier, Natalie J Shiff, Chenglong Han, May Shawi, William Tillett, Phillip J Mease
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis. Rheumatology and therapy 11 (2) (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Stefan Siebert, Laura C Coates, Larissa Valor-Méndez, Siba P Raychaudhuri, Warner Chen, Sheng Gao, Loqmane Seridi, Soumya D Chakravarty, May Shawi, Frederic Lavie, Mohamed Sharaf, Miriam Zimmermann, Alexa P Kollmeier, Xie L Xu, Proton Rahman, Phillip J Mease, Atul A Deodhar
Modulation of IL-23 Signaling With Guselkumab in Biologic-Naïve Patients Versus TNF Inhibitor-Inadequate Responders With Active Psoriatic Arthritis. Arthritis & rheumatology (Hoboken, N.J.) (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Jeffrey R Curtis, Iain B McInnes, Proton Rahman, Dafna D Gladman, Steven Peterson, Feifei Yang, Oluwakayode Adejoro, Alexa P Kollmeier, Natalie J Shiff, Chenglong Han, May Shawi, William Tillett, Phillip J Mease
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis. Rheumatology and therapy 11 (2) (2024)
Stefan Siebert, Laura C Coates, Larissa Valor-Méndez, Siba P Raychaudhuri, Warner Chen, Sheng Gao, Loqmane Seridi, Soumya D Chakravarty, May Shawi, Frederic Lavie, Mohamed Sharaf, Miriam Zimmermann, Alexa P Kollmeier, Xie L Xu, Proton Rahman, Phillip J Mease, Atul A Deodhar
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis. Arthritis & rheumatology (Hoboken, N.J.) 76 (6) (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Jeffrey R Curtis, Iain B McInnes, Proton Rahman, Dafna D Gladman, Steven Peterson, Feifei Yang, Oluwakayode Adejoro, Alexa P Kollmeier, Natalie J Shiff, Chenglong Han, May Shawi, William Tillett, Phillip J Mease
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis. Rheumatology and therapy (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Stefan Siebert, Laura C Coates, Larissa Valor-Méndez, Siba P Raychaudhuri, Warner Chen, Sheng Gao, Loqmane Seridi, Soumya D Chakravarty, May Shawi, Frederic Lavie, Mohamed Sharaf, Miriam Zimmermann, Alexa P Kollmeier, Xie L Xu, Proton Rahman, Phillip J Mease, Atul A Deodhar
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis. Arthritis & rheumatology (Hoboken, N.J.) (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Bruce E Strober, Laura C Coates, Mark G Lebwohl, Atul Deodhar, Evan Leibowitz, Katelyn Rowland, Alexa P Kollmeier, Megan Miller, Yanli Wang, Shu Li, Soumya D Chakravarty, Daphne Chan, May Shawi, Ya-Wen Yang, Diamant Thaҫi, Proton Rahman
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis. Drug safety (2023)
Phillip J Mease, Alice B Gottlieb, Philip S Helliwell, Iain B McInnes, Soumya D Chakravarty, Emmanouil Rampakakis, Alexa P Kollmeier, Xie L Xu, May Shawi, Frederic Lavie, Kishimoto Mitsumasa, Proton Rahman
Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment. Clinical rheumatology (2023)
Alexa P Kollmeier, A Greenspan, X L Xu, P E Silkoff, E S Barnathan, M J Loza, J Jiang, B Zhou, B Chen, R L Thurmond
Phase 2a, randomized, double-blind, placebo-controlled, multicentre, parallel-group study of an H4 R-antagonist (JNJ-39758979) in adults with uncontrolled asthma. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 48 (8) (2018)